Provention Bio
United States
189 articles about Provention Bio
-
Trial data showed a two-week course delayed the onset of diabetes by as much as two years in clinical patients.
-
A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years
6/9/2019
Results from the NIH-Sponsored "At-Risk" Study Published in The New England Journal of Medicine and Presented at the American Diabetes Association Annual Meeting
-
Provention Bio Reports First Quarter 2019 Financial Results
5/8/2019
PROTECT Pivotal Phase 3 Clinical Study Initiated in Patients with Recent Onset Type 1 Diabetes Top line Data Results for PRINCE and At-Risk Clinical Trials Expected in 2019
-
Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
5/8/2019
Top-line results from its Phase 1b PULSE study which evaluated PRV-300, an anti-TLR3 monoclonal antibody, in patients with active, moderate-to-severe ulcerative colitis
-
Provention Bio Completes Enrollment of Phase 2a PRINCE Clinical Trial with PRV-6527 in Patients with Moderate to Severe Crohn's Disease
4/24/2019
Top-line Data Anticipated in the Fourth Quarter of 2019
-
Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes
4/9/2019
Pivotal Study to Evaluate Potential of Anti-CD3 Monoclonal Antibody to Intercept Type 1 Diabetes
-
BioSpace Movers and Shakers: April 5
4/5/2019
Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more. -
Provention Bio Announces Key Additions to its Senior Management Team
4/2/2019
Strengthens Leadership Team with Appointment of Douglas Jacobstein, M.D. as V.P. of Clinical Development and Alex Rabiee as V.P. of Business Development
-
BioSpace Movers and Shakers: March 29
3/29/2019
Biotech and pharma companies bring on new talent to strengthen leadership teams and boards. -
Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors
3/28/2019
Dr. Bluestone is a World-renowned Expert and Academic Leader in Immune Tolerance Research
-
Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
3/19/2019
Provention Bio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update.
-
Provention Bio to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 19, 2019
3/12/2019
Provention Bio, Inc., a clinical-stage biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, announced it will host a conference call and live audio webcast on Tuesday, March 19, 2019, at 4:30 p.m. ET.
-
Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference
2/13/2019
Provention Bio, Inc. (Nasdaq: PRVB), announced today its Chief Executive Officer, Ashleigh Palmer, along with other members of Provention's executive management team, will participate in a fireside chat presentation at the 8th Annual Leerink Partners Global Healthcare Conference being held February 27-March 1, 2019, at the Lotte New York Palace in New York City.
-
Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D)
1/28/2019
Provention is currently developing PRV-101 as a polyvalent vaccine for acute coxsackie virus infection and to potentially prevent the onset of T1D
-
Provention Bio Announces Publication in "Expert Review of Vaccines" Describing the Scientific Rationale for Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B
1/3/2019
Provention is currently developing PRV-101 as a vaccine for acute coxsackie infection and to potentially prevent the onset of T1D
-
Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium
11/28/2018
C-Path's T1D Consortium is focused on understanding the scientific and regulatory expectations associated with the application of biomarkers used to optimize clinical trial designs in this disease.
-
Provention Bio Reports Third Quarter 2018 Financial Results and Provides Business Update
11/8/2018
Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m., ET
-
Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
11/5/2018
Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714
-
Provention Bio to Report Third Quarter 2018 Financial Results and Host Conference Call on Thursday, November 8, 2018
11/1/2018
Provention Bio, Inc. announced today it will host a conference call and live audio webcast on Thursday, November 8, 2018, at 8:30 a.m. ET.
-
Provention Bio Announces Completion of Enrollment of Phase 1b Clinical Trial of PRV-300 in Moderate-to-Severe Ulcerative Colitis
10/23/2018
Top-line data from the "PULSE"clinical trial expected in the second quarter of 2019